Moderna Inc. entered into a settlement with Arbutus Biopharma and Genevant Sciences that resolves all worldwide litigation over its use of lipid‑nanoparticle (LNP) technology in its COVID‑19 and RSV vaccines. The agreement calls for a $950 million upfront payment in July 2026 and a potential $1.3 billion contingent payment that depends on the outcome of Moderna’s appeal of a Section 1498 decision. In exchange, Genevant granted Moderna a global non‑exclusive license to its LNP platform for infectious‑disease applications and a covenant not to sue for certain patents related to Moderna’s products.
The settlement removes a long‑running legal overhang that had threatened Moderna’s ability to commercialize its vaccine portfolio. With the litigation risk eliminated, the company can focus on its pipeline, including the RSV vaccine mRESVIA® and next‑generation COVID‑19 candidates. The payout, while sizable, is manageable given Moderna’s cash position—projected year‑end 2026 cash and equivalents of $4.5 billion to $5.0 billion—and the decline in COVID‑19 vaccine revenue, which fell 40% year‑over‑year to $1.94 billion in 2025.
Stéphane Bancel, CEO, said the settlement “removes uncertainty and allows us to turn our full focus to Moderna’s exciting near‑term future.” The comment underscores the company’s intent to shift resources from litigation defense to product development and commercialization.
Investors welcomed the settlement, citing the removal of a potentially large royalty liability and the clarity it brings to Moderna’s financial outlook. The agreement also provides a clean slate for future licensing negotiations and reduces the risk of additional litigation costs that could have impacted the company’s profitability.
The settlement does not alter Moderna’s existing guidance for 2026, but it strengthens the company’s balance sheet and supports its strategy to grow beyond COVID‑19 vaccines. With the legal risk removed, management can pursue aggressive pipeline development and maintain confidence in its long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.